Literature DB >> 7531901

Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection.

J T Bishoff1, A Reyes, I M Thompson, M J Harris, S R St Clair, L Gomella, C A Butzin.   

Abstract

OBJECTIVES: The prevalence of pelvic lymph node metastases in men with clinically localized prostate cancer has decreased dramatically over the past decade, possibly due to efforts at early detection. With a significantly lower incidence of pelvic node involvement, it may be possible to identify a segment of patients for whom pelvic lymph node dissection (PLND) may be omitted. This study was conducted to develop a method to select patients for whom PLND could be omitted.
METHODS: We analyzed serum prostate-specific antigen (PSA), clinical stage, biopsy Gleason score, and final pathologic stage in 481 men with clinically localized prostate cancer. These variables were compared to the risk of positive pelvic lymph nodes.
RESULTS: Logistic regression analysis determined that combining all three variables provided the best determination of final pathologic stage. A series of probability curves have been created to estimate the risk of positive lymph nodes in a given patient. Based on the distribution of patients in this study and using these probability functions, PLND could be avoided in up to 50% of patients with localized prostate cancer diagnosed by contemporary methods.
CONCLUSIONS: In properly selected patients, pelvic lymphadenectomy can be omitted in the staging and treatment of localized prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531901     DOI: 10.1016/0090-4295(95)80017-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  14 in total

Review 1.  [The role of pelvic lymphadenectomy in clinically localised prostate cancer].

Authors:  M Schumacher; F C Burkhard; U E Studer
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

Review 2.  Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors.

Authors:  Samdeep K Mouli; Lee C Zhao; Reed A Omary; C Shad Thaxton
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

Review 3.  Sentinel node evaluation in prostate cancer.

Authors:  Ramkishen Narayanan; Timothy G Wilson
Journal:  Clin Exp Metastasis       Date:  2018-09-05       Impact factor: 5.150

Review 4.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

5.  The importance of pelvic lymph node dissection in men with clinically localized prostate cancer.

Authors:  Mohamad E Allaf; Alan W Partin; H Ballentine Carter
Journal:  Rev Urol       Date:  2006

6.  Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer.

Authors:  Matthew H Hayn; Heather Orom; Vickie L Shavers; Martin G Sanda; Mark Glasgow; James L Mohler; Willie Underwood
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

7.  11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction.

Authors:  Mohammed Haseebuddin; Farrokh Dehdashti; Barry A Siegel; Jingxia Liu; Elizabeth B Roth; Kenneth G Nepple; Cary L Siegel; Keith C Fischer; Adam S Kibel; Gerald L Andriole; Tom R Miller
Journal:  J Nucl Med       Date:  2013-03-07       Impact factor: 10.057

8.  Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy.

Authors:  Michael A Liss; Kerrin Palazzi; Sean P Stroup; Ramzi Jabaji; Omer A Raheem; Christopher J Kane
Journal:  World J Urol       Date:  2013-03-20       Impact factor: 4.226

9.  Is there a relationship between the number of lymph nodes and disease parameters in patients who underwent retropubic prostatectomy.

Authors:  Aslan Demir; Mert Ali Karadağ; Levent Türkeri
Journal:  Int Urol Nephrol       Date:  2014-03-25       Impact factor: 2.370

10.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.